* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Guidelines for antimicrobial therapy of urinary tract
Survey
Document related concepts
Transcript
Guidelines for antimicrobial therapy of urinary tract infections in Taiwan Infectious Diseases Society of the Republic of China, Medical foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, Lee CY’s Research Foundation for Pediatric Infectious Diseases and Vaccine 2000;33:271-272 J Microbiol Immunol Infect A consensus conference for establishing guidelines for antimicrobial therapy of urinary tract infections in Taiwan was held on March 11, 2000, following a symposium on urinary tract infections(UTIs) held in conjunction by the Infectious Diseases Society of the Republic of China(IDSROC), the Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, and Lee CY’s Research Foundation for Pediatric parties to this consensus conference included board members of the IDSROC, and experts in the field of infectious disease. This is the second consensus conference of this nature, and abided b the three principles established during the first consensus conference on antimicrobial therapy of pneumonia in Taiwan, held in 1999: 1.Establishment of guidelines from the viewpoint of primary care physicians. 2.Antimicrobial agents recommended in the guidelines were agents already marked in Taiwan. 3.Guidelines were based on academic principles rather than the regulations of the Bureau of Natonal Health Insurance on antibiotic usage. In addition, the following two points were also considered: 1.Guidelines were tailored to the local epidemiology, including commonly seen pathogens and antimicrobial resistance patterns. 2.Guidelines included recommendations on prophylactic antimicrobial usage. Treatment guidelines were passed through the board of IDSROC, and a copy was sent to primary care physicians, in the hope fensuring appropriate use of antimicrobial agents in the community. These treatment guidelines were published as a supplement in the Journal of Immunology, Microbiology and Infection, to serve as a reference to all practicing physicians in Taiwan. Guidelines for antimicrobial therapy of urinary tract infections Diagnosis Drug of choice Alternative choice Asymptomatic bacteriuria Nitrofurantoin 1o or 2o cephalosporins Trimethoprimb Trimethoprim/sulfamethoxazoleb Ampicillin or amoxicillinc Ampicillin/sulbactamc amoxicillin/clavulanatec Acute bacterial cystitis Nitrofurantoin 1o or 2o cephalosporins Trimethoprim Trimethoprim/sulfamethoxazoleb Quinolonesd Ampicillin or amoxicillinc Ampicillin/sulbactamc Amoxicillin/clavulanatec Fluoroquinolonese Guidelines for antimicrobial therapy of urinary tract infections Diagnosis Drug of choice Acute uncomplicated Trimethoprim/sulfametho pyelonephritis xazole 1o or 2o cephalosporins Aminoglycosides Acute complicated pyelonephritis/ emphysematous pyelonephritis/renal and perinephric abscess 1o or 2o cephalosporins or ampicillin or amoxicillin±Aminoglycos ides Trimethoprim/sulfametho xazole Alternative choice Ampicillin or amoxicillinc Ampicillin/sulbactamc Amoxicillin/clavulanatec Aminoglycosides(single)+ 1o or 2o cephalosporins 3o or 4o cephalosporins Ticarcillin/clavulanate Piperacillin/tazobactam Aztreonam Imipenem or meropenem Fluoroquinolonese Diagnosis Drug of choice Acute bacterial prostatitis Ampicillin or amoxicillin 3o cephalosporins Trimethoprim/sulfamethoxa zole Chronic bacterial prostatitis Trimethoprim/sulfamethoxa zole Fluoroquinolones Alternative choice Fluoroquinolonese Diagnosis Drug of choice Alternative choice Nosocomial/catheterrelated UTIs 3o or 4o cephalosporins Ureidopenicillins Fluoroquinolonese Ampicillin or amoxicillinf ± Aminoglycosides Imipenem or meropenem UTIs in pregnancy Ampicillin or amoxicillinc Nitrofurantoin 1o or 2o cephalosporins 3o or 4o cephalosporins Ureidopenicillins Diagnosis Drug of choice Alternative choice UTIs in children Ampicillin or amoxicillinc 3o or 4o or 1o or 2o cephalosporins cephalosporins + Aminoglycosides Trimethoprim/sulfamethoxa zole Suppressive recurrent UTIs Nitrofurantoin Trimethoprim Trimethoprim/sulfamethoxa zole Consensus Conference Participants (in alphabetical order): Feng-Yee Chang, Shan-Chwen Chang, Yao-Shen Chen, Ming-Yuan Chou, Mong-Ling Chu, ChangPhone Fung, Wei-Chuan Hsieh, Po-Ren Hsueh, Clement C.S. Hsu, Cheng-Hua Huang, Fu-Yuan Huang, Kun-Yen Huang, Yhu-Chering Huang, Chien-Ching Hung, Kao-Pin Hwang, Chi-Kan Lan, Yeu-Jan Lau, Cheng-Yi Liu, Ching-Chuan Liu, Yung-Ching Liu, Kwen-Tay Luh, Fu-Der Wang, LihShinn Wang, Wing-Wai Wong, Muh-Yong Yen, Kwok-Woon Yu. Dosage of Quinolones in Patients with normal and reduced renal function Norrnal Renal Function Quinolone Oral Intravenous Nalidixic acid 500-1000mg q6h - Cinoxacin 250mg q6h - Norfloxacin 400mg q12h - Ciprofloxacin 250-750mg q12h 200-400mg q12h Ofloxacin 200-400mg q12h 200-400mg q12h Pefloxacin 400mg q12h 400mg q12h Dosage of Quinolones in Patients with normal and reduced renal function Norrnal Renal Function Quinolone Oral Intravenous Enoxacin 200-400mg q12h - Lomefloxacin 400mg q24h - Sparfloxacin 400mg loading dose, then 200mg q24h - Levofloxacin 500mg q24h 500mg q24h Grepafloxacin 400-600mg q24h - Trovafloxacin 200-300mg q24h 200-300mg q24h Available b-lactamase inhibitors and b-lactam antibiotic combinations Active β-lactamase antibiotics inhibitor Amoxicillin Clavulanate Augmentin Ticarcillin Clavulanate Timentin Only parenteral Ampicillin Sulbactam Unasyn Only parenteral Piperacillin Tazobactam Tazocin Only parenteral; most active antibiotic in vitro Trade name Comment The major Cephalosporins First Generation Second Generation Third Generation Parenteral Parenteral Parenteral Cephalothin (Keflin) Cefamandole (Mandol) Cefotaxime (Claforan) Cefazolin (Ancef, Kefzol) Cefoxitin (Mefoxin) Cefoperazone (Cefobid) Cephapirin (Cefadyl) Cefuroxime (Zinacef) Ceftizoxime (Cefizox) Cephradine (Velosef) Cefotentan (Cefotan) Ceftriaxone (Rocephin) Ceftazidime (Fortaz, Tazidime, or Tazicef) Fourth Generation Cefepime(Maxipime)